See more : Indian Oil Corporation Limited (IOC.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Pieris Pharmaceuticals, Inc. (PIRS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pieris Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Telenor ASA (TELNF) Income Statement Analysis – Financial Results
- Guangzhou Jointas Chemical Co., Ltd. (002909.SZ) Income Statement Analysis – Financial Results
- Kilitch Drugs (India) Limited (KILITCH.BO) Income Statement Analysis – Financial Results
- GasLog Partners LP (GLOP) Income Statement Analysis – Financial Results
- Lovable Marketing Group,inc. (9254.T) Income Statement Analysis – Financial Results
Pieris Pharmaceuticals, Inc. (PIRS)
About Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42.81M | 25.90M | 31.42M | 29.32M | 46.28M | 29.10M | 25.28M | 5.83M | 2.93M | 5.37M | 9.88M | 11.38M |
| Cost of Revenue | 41.80M | 2.78M | 2.37M | 46.53M | 55.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.55M | 0.00 |
| Gross Profit | 1.01M | 23.12M | 29.05M | -17.21M | -8.72M | 29.10M | 25.28M | 5.83M | 2.93M | 5.37M | 12.43M | 11.38M |
| Gross Profit Ratio | 2.36% | 89.27% | 92.46% | -58.68% | -18.84% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 125.78% | 100.00% |
| Research & Development | 41.80M | 52.98M | 66.66M | 46.53M | 55.00M | 41.49M | 22.29M | 19.70M | 8.24M | 5.60M | 9.41M | 10.85M |
| General & Administrative | 16.85M | 16.39M | 16.59M | 16.71M | 18.44M | 18.44M | 17.58M | 8.89M | 8.37M | 6.96M | 2.46M | 2.71M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 280.86K |
| SG&A | 16.85M | 16.39M | 16.59M | 16.71M | 18.44M | 18.44M | 17.58M | 8.89M | 8.37M | 6.96M | 2.46M | 2.99M |
| Other Expenses | 13.91M | -8.17M | -3.69M | -3.66M | -26.00K | 1.80M | -2.10M | 119.50K | 10.91K | 3.00K | 6.31K | 0.00 |
| Operating Expenses | 72.57M | 61.20M | 79.56M | 63.24M | 73.44M | 59.93M | 39.87M | 28.59M | 16.61M | 12.56M | 9.33M | 13.53M |
| Cost & Expenses | 72.57M | 61.20M | 79.56M | 63.24M | 73.44M | 59.93M | 39.87M | 28.59M | 16.61M | 12.56M | 9.33M | 13.53M |
| Interest Income | 1.85M | 721.00K | 4.00K | 511.00K | 1.71M | 1.96M | 152.00K | 2.32K | 0.00 | 0.00 | 0.00 | 177.13K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.95M | 2.32K | 184.65K | 2.65M | 493.94K | 0.00 |
| Depreciation & Amortization | 1.78M | 2.78M | 2.37M | 2.13M | 1.04M | 570.00K | 369.00K | 361.38K | 307.91K | 366.98K | 384.68K | 378.32K |
| EBITDA | -22.76M | -30.50M | -43.37M | -31.61M | -26.12M | -30.26M | -14.23M | -22.40M | -13.37M | -6.83M | 938.50K | -1.80M |
| EBITDA Ratio | -53.17% | -136.29% | -153.24% | -108.43% | -56.43% | -103.99% | -56.28% | -390.33% | -466.25% | -134.11% | 9.56% | -15.83% |
| Operating Income | -29.76M | -43.47M | -51.83M | -33.92M | -27.16M | -30.83M | -14.59M | -22.76M | -13.68M | -7.20M | 553.83K | -2.18M |
| Operating Income Ratio | -69.51% | -167.84% | -164.97% | -115.68% | -58.68% | -105.94% | -57.74% | -390.33% | -466.62% | -134.17% | 5.61% | -19.15% |
| Total Other Income/Expenses | 5.21M | 10.20M | 6.09M | -3.15M | 1.69M | 3.77M | -1.95M | 122.00K | -173.74K | -2.65M | -487.63K | -140.55K |
| Income Before Tax | -24.54M | -33.28M | -45.74M | -37.07M | -25.47M | -27.07M | -16.54M | -22.64M | -13.85M | -9.85M | 66.20K | -2.32M |
| Income Before Tax Ratio | -57.33% | -128.47% | -145.58% | -126.41% | -55.03% | -93.01% | -65.46% | -388.24% | -472.55% | -183.60% | 0.67% | -20.39% |
| Income Tax Expense | 0.00 | -2.02M | -2.37M | 164.00K | -1.71M | -312.00K | 1.10M | 161.97K | 203.87K | -18.00 | 487.63K | 22.00 |
| Net Income | -24.54M | -31.25M | -43.37M | -37.23M | -23.76M | -26.75M | -17.65M | -22.80M | -14.06M | -9.85M | 66.20K | -2.32M |
| Net Income Ratio | -57.33% | -120.66% | -138.03% | -126.97% | -51.33% | -91.93% | -69.82% | -391.02% | -479.50% | -183.59% | 0.67% | -20.39% |
| EPS | -21.80 | -33.71 | -53.75 | -54.67 | -37.54 | -40.32 | -32.14 | -43.73 | -32.70 | -20.62 | 0.45 | -38.68 |
| EPS Diluted | -21.80 | -33.71 | -53.75 | -54.67 | -37.54 | -40.32 | -32.14 | -43.73 | -32.70 | -20.62 | 0.45 | -38.68 |
| Weighted Avg Shares Out | 1.13M | 927.15K | 806.84K | 681.01K | 632.81K | 663.51K | 549.14K | 521.41K | 429.91K | 477.68K | 477.68K | 59.99K |
| Weighted Avg Shares Out (Dil) | 1.13M | 927.15K | 806.84K | 681.01K | 632.81K | 663.51K | 549.14K | 521.41K | 429.91K | 477.68K | 477.68K | 59.99K |
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference
Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. - PIRS
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. – PIRS
Shareholder Alert: Ademi LLP investigates whether Pieris Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders
Why Is Pieris Pharmaceuticals (PIRS) Stock Up 77% Today?
Source: https://incomestatements.info
Category: Stock Reports